3,225 reports of this reaction
3.5% of all RISANKIZUMAB RZAA reports
#2 most reported adverse reaction
DRUG INEFFECTIVE is the #2 most commonly reported adverse reaction for RISANKIZUMAB RZAA, manufactured by AbbVie Inc.. There are 3,225 FDA adverse event reports linking RISANKIZUMAB RZAA to DRUG INEFFECTIVE. This represents approximately 3.5% of all 92,878 adverse event reports for this drug.
RISANKIZUMAB RZAA has an overall safety score of 78 out of 100. Patients taking RISANKIZUMAB RZAA who experience drug ineffective should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG INEFFECTIVE is moderately reported among RISANKIZUMAB RZAA users, representing a notable but not dominant share of adverse events.
In addition to drug ineffective, the following adverse reactions have been reported for RISANKIZUMAB RZAA:
The following drugs have also been linked to drug ineffective in FDA adverse event reports:
DRUG INEFFECTIVE has been reported as an adverse event in 3,225 FDA reports for RISANKIZUMAB RZAA. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG INEFFECTIVE accounts for approximately 3.5% of all adverse event reports for RISANKIZUMAB RZAA, making it one of the most commonly reported side effect.
If you experience drug ineffective while taking RISANKIZUMAB RZAA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.